Biomarker hunt: could IFN-Gamma guide melanoma treatment?

NCT ID NCT07436390

Completed Knowledge-focused Sponsor: Institute of Oncology Ljubljana Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked at 132 people with advanced melanoma to see if levels of a protein called interferon-gamma (IFN-γ) in their tumors or blood could predict how well they would respond to first-line immunotherapy drugs like pembrolizumab, nivolumab, or a combination. The goal is to find a reliable biomarker to personalize treatment and avoid giving ineffective therapies. The study also explored whether gut bacteria play a role in treatment outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pembrolizumab, Nivolumab, Ipilimumab/Nivolumab
What this could lead to: If successful, this could help doctors choose the right immunotherapy for each patient, improving response rates and reducing unnecessary side effects.
What could go wrong: This is an observational study, not a treatment trial. The biomarker may not reliably predict response, and results may not change clinical practice immediately.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma metastatic melanoma skin cancer skin neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT MELANOMA METASTATIC MELANOMA SKIN CANCER

Contacts and locations

Locations

Institute of Oncology Ljubljana

Ljubljana, 1000, Slovenia

More trials for these conditions

Other studies related to the condition(s) this trial covers.